Doç. Dr. DENİZ CAN GÜVEN

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , cilt.41, sa.30, ss.4821-4822, 2023 (SCI-Expanded, Scopus)

54. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

EROL C., HAFIZOĞLU E., aykan m. b., GÜVEN D. C., Dursun B., Hizal M., et al.

ACTA ONCOLOGICA TURCICA , cilt.56, sa.2, ss.170-179, 2023 (TRDizin)

55. Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer

Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., et al.

Strahlentherapie und Onkologie , cilt.199, sa.8, ss.761-772, 2023 (SCI-Expanded, Scopus)

56. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives

ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.

European Archives of Oto-Rhino-Laryngology , cilt.280, sa.8, ss.3541-3556, 2023 (SCI-Expanded, Scopus)

57. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , cilt.34, sa.6, ss.783-790, 2023 (SCI-Expanded, Scopus)

58. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.7, ss.3599-3606, 2023 (SCI-Expanded, Scopus)

59. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.8, ss.4141-4148, 2023 (SCI-Expanded, Scopus)

60. SMART syndrome: a case report

Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.

ACTA NEUROLOGICA BELGICA , cilt.123, sa.3, ss.1137-1140, 2023 (SCI-Expanded, Scopus)

61. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.

Medicine (United States) , cilt.102, sa.18, 2023 (SCI-Expanded, Scopus)

62. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma

GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.

European Archives of Oto-Rhino-Laryngology , cilt.280, sa.5, ss.2471-2478, 2023 (SCI-Expanded, Scopus)

63. Learning From Failure: Negative Trials in Oncology

Nardo M., GÜVEN D. C., Yikilmaz A. S., Singh S., Ahmed J.

Journal of Immunotherapy and Precision Oncology , cilt.6, sa.2, ss.59-60, 2023 (Scopus)

64. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.

Future oncology (London, England) , cilt.19, sa.10, ss.727-736, 2023 (SCI-Expanded, Scopus)

65. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.

Clinics and Research in Hepatology and Gastroenterology , cilt.47, sa.3, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

66. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer

Akagunduz B., Guven D. C., Ozer M., Okten I. N., Atag E., Unek İ. T., et al.

Journal of Geriatric Oncology , cilt.14, sa.2, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

67. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , cilt.152, ss.679-685, 2023 (SCI-Expanded, Scopus)

68. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.3, ss.243-256, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

69. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçi M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., et al.

Journal of Oncological Science , cilt.9, sa.2, ss.72-78, 2023 (Scopus, TRDizin)

70. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.

Journal of Oncological Science , cilt.9, sa.1, ss.33-37, 2023 (Scopus, TRDizin)

71. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , cilt.23, sa.10, ss.1049-1059, 2023 (SCI-Expanded, Scopus)

72. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.

Frontiers in Molecular Biosciences , cilt.9, 2022 (SCI-Expanded, Scopus)

73. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.12, ss.3547-3555, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

74. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , cilt.15, sa.4, ss.307-310, 2022 (ESCI, Scopus)

75. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.

BREAST , cilt.66, ss.85-88, 2022 (SCI-Expanded, Scopus)

76. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.8, ss.1807-1811, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

77. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , cilt.27, sa.11, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

78. Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis

BAŞ O., Erul E., GÜVEN D. C., AKSOY S.

SUPPORTIVE CARE IN CANCER , cilt.30, sa.11, ss.9071-9078, 2022 (SCI-Expanded, Scopus)

79. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine

Carloni R., Rizzo A., Ricci A. D., Di Federico A., De Luca R., GÜVEN D. C., et al.

TRANSLATIONAL ONCOLOGY , cilt.25, 2022 (SCI-Expanded, Scopus)

80. The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges

GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.

APPLIED SCIENCES-BASEL , cilt.12, sa.20, 2022 (SCI-Expanded, Scopus)

81. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.17, 2022 (SCI-Expanded, Scopus)

82. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis

Rizzo A., Carloni R., Ricci A. D., Di Federico A., GÜVEN D. C., YALÇIN Ş., et al.

JOURNAL OF PERSONALIZED MEDICINE , cilt.12, sa.8, 2022 (SCI-Expanded, Scopus)

83. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.

JOURNAL OF CLINICAL MEDICINE , cilt.11, sa.15, 2022 (SCI-Expanded, Scopus)

84. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

TABAN H., GÜVEN D. C., Kilickap S.

CUREUS JOURNAL OF MEDICAL SCIENCE , cilt.14, sa.8, 2022 (ESCI)

85. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded, Scopus)

86. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.28, sa.4, ss.785-793, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

87. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.

CANCERS , cilt.14, sa.11, 2022 (SCI-Expanded, Scopus)

88. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.

Guven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.

JOURNAL OF CLINICAL ONCOLOGY , cilt.40, sa.16, 2022 (SCI-Expanded, Scopus)

89. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., et al.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.53, sa.2, ss.282-288, 2022 (ESCI, Scopus) Sürdürülebilir Kalkınma

90. The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials

GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.174, 2022 (SCI-Expanded, Scopus)

91. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , cilt.27, 2022 (SCI-Expanded, Scopus)

92. HER2-low breast cancer could be associated with an increased risk of brain metastasis

GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , cilt.27, sa.2, ss.332-339, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

93. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , cilt.8, sa.3, ss.143-147, 2022 (Scopus, TRDizin)

94. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1551-1558, 2022 (SCI-Expanded, Scopus, TRDizin)

95. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.52, sa.5, ss.1559-1568, 2022 (SCI-Expanded, Scopus, TRDizin)

96. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

GÜRLER F., Ilhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., et al.

ANTI-CANCER DRUGS , cilt.33, sa.1, 2022 (SCI-Expanded, Scopus)

97. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.

FUTURE ONCOLOGY , cilt.18, ss.323-331, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

98. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.6, sa.1, ss.59-63, 2022 (ESCI, TRDizin) Sürdürülebilir Kalkınma

99. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats

AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.12, ss.1049-1056, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

100. Assessment of abuse and related factors in older patients with cancer

Akagunduz B., Altin Z., Atci M. M., Ozer M., GÜVEN D. C., Cil I., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.12, ss.7957-7964, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

101. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.

CURRENT PROBLEMS IN CANCER , cilt.45, sa.6, 2021 (SCI-Expanded, Scopus)

102. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , cilt.168, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

103. Thirty-day mortality rates after immunotherapy initiation

SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., et al.

IMMUNOTHERAPY , cilt.13, ss.1419-1426, 2021 (SCI-Expanded, Scopus)

104. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.

FRONTIERS IN ONCOLOGY , cilt.11, 2021 (SCI-Expanded, Scopus)

105. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , cilt.73, sa.10, ss.1957-1963, 2021 (SCI-Expanded, Scopus)

106. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.

FUTURE ONCOLOGY , cilt.17, ss.4405-4413, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

107. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus)

108. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.9, ss.5417-5423, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

109. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , cilt.15, sa.13, ss.1123-1130, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

110. Sarcopenia and anthracycline cardiotoxicity in patients with cancer

BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

111. Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms

GÜVEN D. C., YALÇIN Ş.

INTERNAL MEDICINE JOURNAL , cilt.51, sa.8, ss.1365-1366, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

112. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.27, sa.5, ss.1281-1283, 2021 (SCI-Expanded, Scopus)

113. Reassurance of patients with cancer on cancer care continuum: a vital strategy to prevent anxiety of COVID-19 collateral damage

GÜVEN D. C.

SUPPORTIVE CARE IN CANCER , cilt.29, ss.3423-3424, 2021 (SCI-Expanded, Scopus)

114. Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review

Yigit E., GÜVEN D. C., AKSOY S., YAZICI G.

CUREUS , cilt.13, sa.6, 2021 (ESCI)

115. A novel agnostic tumor: NTRKoma

Ayasun R., GÜVEN D. C., Gullu İ. H.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.27, sa.4, ss.802-803, 2021 (SCI-Expanded, Scopus)

116. Artificial intelligence method to predict overall survival of hepatocellular carcinoma

ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., et al.

Hepatology Forum , cilt.2, sa.2, ss.64-68, 2021 (Scopus)

117. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.36, 2021 (SCI-Expanded, Scopus)

118. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer

Turker S., Cilbir E., GÜVEN D. C., Karacin C., YALÇIN Ş.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.17, sa.2, ss.510-515, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

119. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.

SUPPORTIVE CARE IN CANCER , cilt.29, sa.4, ss.2029-2035, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

120. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.

TURKISH JOURNAL OF UROLOGY , cilt.47, sa.2, ss.113-119, 2021 (ESCI, Scopus, TRDizin)

121. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.

CANCER RESEARCH , cilt.81, sa.4, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

122. Thyroid gland metastasis mimicking thyroid carcinoma in a lung cancer patient and dramatic response to crizotinib: A case report

Erul E., GÜVEN D. C., ŞAHİN T. K., Gullu İ. H.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , cilt.69, sa.1, ss.98-101, 2021 (ESCI, Scopus, TRDizin)

123. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters

GÜVEN D. C., ŞAHİN T. K., AKSOY S.

BREAST JOURNAL , cilt.26, sa.12, ss.2435-2436, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

124. Cancer incidence in Behcet's disease

GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEN B., AKTAŞ B. Y., KİRAZ S., et al.

IRISH JOURNAL OF MEDICAL SCIENCE , cilt.189, sa.4, ss.1209-1214, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

125. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., et al.

EUROPEAN JOURNAL OF CANCER CARE , cilt.29, sa.6, 2020 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

126. Effects of adenosine triphosphate on vandetanib induced skin damage in rats

Akagunduz B., ÖZÇİÇEK F., Kara A. V., GÜVEN D. C., YAZICI G. N., Coban A., et al.

CUTANEOUS AND OCULAR TOXICOLOGY , cilt.39, sa.4, ss.323-327, 2020 (SCI-Expanded, Scopus)

127. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.

CLINICAL COLORECTAL CANCER , cilt.19, sa.3, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

128. All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past

Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , cilt.43, sa.9, ss.676, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

129. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19

GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.

FRONTIERS IN ONCOLOGY , cilt.10, 2020 (SCI-Expanded, Scopus)

130. Cancer incidence in Behcet's Disease.

Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.

JOURNAL OF CLINICAL ONCOLOGY , cilt.38, sa.15, 2020 (SCI-Expanded, Scopus)

131. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications

GÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.

FUTURE ONCOLOGY , cilt.16, sa.9, ss.497-506, 2020 (SCI-Expanded, Scopus)

132. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.2, ss.496-499, 2020 (SCI-Expanded, Scopus)

133. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.1, ss.256-258, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

134. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.

JOURNAL OF BUON , cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded, Scopus)

135. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy

AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.

EXPERT REVIEW OF ANTICANCER THERAPY , cilt.19, sa.7, ss.589-601, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

136. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients

Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

BIOMARKERS IN MEDICINE , cilt.13, sa.9, ss.725-735, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

137. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia

BİLGİN E., DİZDAR Ö., Guven D. C., Ceylan S., AYBI Ö., FIRLATAN B., et al.

Rheumatology International , cilt.39, sa.6, ss.1045-1051, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

138. Evaluation of cancer risk in patients with periodontal diseases

Guven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , cilt.49, sa.3, ss.826-831, 2019 (SCI-Expanded, Scopus, TRDizin)

139. A rare cause of proximal muscle weakness: immune necrotising myopathy

GÜVEN D. C., ERDEN A., KILIÇ L., ERDEM ÖZDAMAR S., KARADAĞ Ö.

SCOTTISH MEDICAL JOURNAL , cilt.63, sa.3, ss.82-86, 2018 (SCI-Expanded, Scopus)

140. Fusobacterium and colorectal carcinogenesis

Guven D. C., DİZDAR Ö.

CARCINOGENESIS , cilt.39, sa.1, ss.84, 2018 (SCI-Expanded, Scopus)

141. Increased cancer risk in patients with periodontitis

DİZDAR Ö., HAYRAN M., Guven D. C., YILMAZ T. B., TAHERI S., AKMAN A. C., et al.

CURRENT MEDICAL RESEARCH AND OPINION , cilt.33, sa.12, ss.2195-2200, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

142. An Unusual Case of Tuberculosis Lenfadenitis Mimicking Tularemia

Başpınar B., HELVACI Ö., GÜVEN D. C., İNKAYA A. Ç.

Turkiye Klinikleri Journal of Internal Medicine , cilt.1, sa.2, ss.111-113, 2016 (Hakemli Dergi)

143. Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

ATEŞ Ö., GÜVEN D. C., BABACAN T., Sunar V., Sarici F., AKSOY S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.26, sa.4, ss.206-214, 2016 (SCI-Expanded, Scopus, TRDizin)

144. Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results

KALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., et al.

ARTHRITIS & RHEUMATOLOGY , cilt.67, 2015 (SCI-Expanded, Scopus)

145. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia

GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.

JOURNAL OF BUON , cilt.19, sa.4, ss.1127, 2014 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 10

1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, (Özet Bildiri)

2. outcomes of patients with resected pancreatic ductal adenocarcinoma

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.

9th international gastrointestinal cancer conference, 6 - 08 Aralık 2019, (Tam Metin Bildiri)

3. MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?

BİLGİN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., et al.

Annual European Congress of Rheumatology (EULAR), Madrid, İspanya, 12 - 15 Haziran 2019, cilt.78, ss.993, (Özet Bildiri)

4. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)